Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation

Japanese Journal of Cancer Research

Volumn 90, Issue 10, 1999, Pages 1117-1129

  Fujii, Shin Ichiro ^a   Shimizu, Kanako ^b   Fujimoto, Koji ^a   Kiyokawa, Tetsuyuki ^a   Shimomura, Taizo ^b   Taniguchi, Osamu ^c   Kinoshita, Moritoshi ^c   Kawano, Fumio ^a  

^a NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Chronic myelogenous leukemia chronic phase; Dendritic cells; Peripheral blood stem cell tramsplantation; T cell receptor usage; Vaccination

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; T LYMPHOCYTE RECEPTOR;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; AUTOTRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VACCINATION;

EID: 0032702775     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00686.x     Document Type: Article

References (32)

1. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H. J., Pralle, H., Hossfeld, D. K., Quisser, W., Loffler, H., Hochhaus, A., Heinze, B., Georgii, A., Bartram, C. R., Griesshammer, M., Bergmann, H., Walther, F., Fett, W., Kleeberg, U. R. and Kabisch, A. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood, 84, 4064-4077 (1994).
2. Shimomura, T., Fujii, S-I., Ezaki, I., Osato, M., Fujimoto, K., Takatsuki, K., Yamamoto, K. and Kawakita, M. Characterisation of T cell receptor β chain mRNA expression in IFN-α-responsive chronic myelogenous leukaemia patients. Br. J. Haematol., 105, 173-180 (1999).
3. Reiffers, J., Mahon, F. X., Boiron, J. M., Faberes, C., Marit, G., Cony-Makhoul, P. and Braustet, A. Autografting in chronic myeloid leukemia: an overview. Leukemia, 10, 385-388 (1996).
4. Bhatia, R., Verfaillie, C. M., Miller, J. S and McGlave, P. B. Autologous transplantation therapy for chronic myelogenous leukemia. Blood, 89, 2623-2634 (1997).
5. Carella, A. M., Simonsson, B., Link, H., Lennard, A., Boogaerts, M., Gorin, N., Tomas-Martinez, J., Dabouz-Harrouche, F., Gautier, L. and Badri, N. Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukemia patients with a poor response to interferon-alpha. Br. J. Haematol., 101, 111-118 (1998).
6. Chervenick, P. A., Ellis, L. D., Pan, S. F. and Lawson, A. L. Human leukemic cells: in vitro growth of colonies containing the Philadelphia (Ph) chromosome. Science, 174, 1134-1136 (1971).
7. Brion, A., Charbord, P., Flesch, M., Deconinck, E., Deschaseux, M., Racadot, E. W. and Cahn, J. Y. Autografting with cultured marrow in CML: problem of hematopoietic reconstitution. Bone Marrow Transplant., 15, S22 (1995).
8. Carella, A. M., Frassoni, F., Podesta, M., Pungolino, E., Pollicardo, N., Ferrero, R. and Soracco, M. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia. J. Hematother., 3, 199-202 (1994).
9. Shlomchik, W. D. and Emerson, S. G. The immunobiology of T cell therapies for leukemias. Acta Haematol., 96, 189-213 (1996).
10. Thomas, R., Davis, L. S. and Lipsky, P. E. Comparative accessory cell function of human peripheral blood dendritic cells and monocytes. J. Immunol., 151, 6840-6852 (1993).
11. Hart, D. N. J. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 90, 3245-3287 (1997).
12. + peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis. Br. J. Haematol., 99, 490-499 (1997).
13. Choudhury, A., Gajewski, J. L., Liang, J. C., Popat, U., Claxton, D. F., Kliche, K.-O., Andreeff, M. and Champlin, R. E. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood, 89, 1133-1142 (1997).
14. Bentz, M., Cabot, G., Moos, M., Speicher, M. R., Ganser, A., Lichter, P. and Dohner, H. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood, 83, 1922-1928 (1994).
15. + hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res., 59, 2150-2158 (1999).
16. Lefkovits, I. "Immunology Methods Manuals" (1997). Academic Press, San Diego, CA.
17. Weidmann, E., Brieger, J., Jahn, B., Hoelzer, D., Bergmann, L. and Mitrou, P. S. Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann. Hematol., 70, 153-158 (1995).
18. Cross, N. C. P., Melo, J. V., Feng, L. and Goldman, J. M. An optimized multiplex polymerase chain reaction (PCR) for detection of bcr-abl fusion mRNA in hematological disorders. Leukemia, 8, 186-189 (1994).
19. Yamamoto, K., Sakoda, H., Nakajima, T., Kato, T., Okubo, M., Dohi, M., Mizushima, Y., Ito, K. and Nishioka, K. Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. Int. Immunol., 4, 1219-1223 (1992).
20. Picker, L. J., Singh, M. K., Zdraveski, Z., Treer, J. R., Waldrop, S. L., Bergstresser, P. R. and Maino, V. C. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood, 86, 1408-1419 (1995).
21. Horowitz, M. M., Gale, R. P.. Sondel, P. M., Goldman, J. M., Kersey, J., Kolb, H. J., Rimm, A. A., Ringden, O., Rozman, C., Speck, B., Truitt, R. L., Zwaan, F. E. and Bortin, M. M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562 (1990).
22. Hughes, T. P., Morgan, G. J., Martiat, P. and Goldman, J. M. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood, 77, 874-878 (1991).
23. Giralt, S., Hester, J., Huh, Y., Hirsh-Ginsber, C., Rondon, G., Seong, D., Lee, M., Gajewski, J., VanBesien, K., Khouri, I., Rakesha, M., Przepiorka, D., Korbling, M., Talpaz, M., Kantarjian, H., Fischer, H., Desseroth, A. and Champlin, R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood, 86, 4337-4343 (1995).
24. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B. and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1, 1297-1302 (1995).
25. Hsu, F. F., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G. and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2, 52-58 (1996).
26. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4, 328-332 (1998).
27. Fujii, S-I., Fujimoto, K., Shimomura, T., Yamamoto, K., Hamada, H. and Kawakita, M. Activated dendritic cells from bone marrow cells of mice administered cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing syngeneic tumor. Blood, 93, 1-9 (1999).
28. + cord blood cell-derived and irradiated tumor cell-primed dendritic cells. Int. J. Hematol., 68, 169-182 (1998).
29. Smit, W. M., Rijnbeek, M., van Bergen, C. A. M., de Paus, R. A., Vervenne, H. A. W., van de Keur, M., Willemze, R. and Falkenburg, J. H. F. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum. Immunol., 53, 216-223 (1997).
30. Lim, S. H. and Coleman, S. Chronic myeloid leukemia as an immunological target. Am. J. Hematol., 54, 61-67 (1997).
31. Papadopoulos, K. P., Suciu-Foca, N., Hesdorffer, C. S., Tugulea, S., Maffei, A. and Harris, P. E. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood, 90, 4938-4946 (1997).
32. Ishiyama, M., Tominaga, H., Shiga, M., Sakamoto, K., Ohkura, Y., Ueno, K. and Ueno, K. Novel cell proliferation and cytotoxicity assays using a tetrazolium salt that produces a water-soluble formazan dye. In Vitro Toxicol., 8, 187-190 (1995).